title: Miliary tuberculosis infection during hepatitis C treatment with sofosbuvir and ledipasvir plus ribavirin.
abstract: Chronic hepatitis C virus (HCV) infection is one of the main causes of chronic liver disease worldwide. In the last 5 years, treatment for HCV infection has experienced a marked development. In 2014, the use of ledipasvir/sofosbuvir with or without concomitant weight-based ribavirin was approved with a very significant increase in the sustained virological response. However, new side effects have been associated. We report the first case of an HCV infected patient treated for 12 wk with the combination of sofosbuvir/ledipasvir plus ribavirin who developed a miliary tuberculosis (TB) infection while on therapy. The patient was a 65-year-old woman, who referred malaise, asthenia, hyporexia, 7 kg weight loss, productive cough, evening fever and night sweats, right after finishing the treatment. The chest computed tomography-scan revealed a superior mediastinal widening secondary to numerous lymphadenopathies with extensive necrosis and bilateral diffuse lung miliary pattern with little subsequent bilateral pleural effusion, highly suggestive of lymph node tuberculosis with lung miliary spread. A bronchoscopy was performed and bronchial suction showed more than 50 acid-alcohol resistant bacillus per line. AMycobacterium tuberculosisDNA was detected in blood by polymerase chain reaction, which confirmed the diagnosis of miliary tuberculosis. Some cases of TB infection have been identified with α-interferon-based therapy and with the triple therapy of pegylated interferon, ribavirin and boceprevir or telaprevir. However, significant infection has not been reported with sofosbuvir/ledipasvir plus ribavirin. We believe that the case is relevant to increase awareness of opportunistic infections and particularly TB infection. Although the international guidelines offer no recommendation regarding TB screening, we wonder whether it would be advisable to screen for opportunistic infections prior to the introduction of HCV therapy.
authors.affiliation: Maria Pilar Ballester-Ferré, Gastroenterology and Hepatology Department, University Clinic Hospital of Valencia, University of Valencia, 46010 Valencia, Spain.
authors.forename: Maria Pilar
authors.initials: MP
authors.lastname: Ballester-Ferré
authors.affiliation: Maria Pilar Ballester-Ferré, Gastroenterology and Hepatology Department, University Clinic Hospital of Valencia, University of Valencia, 46010 Valencia, Spain.
authors.forename: Fernando
authors.initials: F
authors.lastname: Martínez
authors.affiliation: Maria Pilar Ballester-Ferré, Gastroenterology and Hepatology Department, University Clinic Hospital of Valencia, University of Valencia, 46010 Valencia, Spain.
authors.forename: Natalia
authors.initials: N
authors.lastname: Garcia-Gimeno
authors.affiliation: Maria Pilar Ballester-Ferré, Gastroenterology and Hepatology Department, University Clinic Hospital of Valencia, University of Valencia, 46010 Valencia, Spain.
authors.forename: Francisco
authors.initials: F
authors.lastname: Mora
authors.affiliation: Maria Pilar Ballester-Ferré, Gastroenterology and Hepatology Department, University Clinic Hospital of Valencia, University of Valencia, 46010 Valencia, Spain.
authors.forename: Miguel A
authors.initials: MA
authors.lastname: Serra
keywords: Hepatitis C; Ledipasvir; Ribavirin; Sofosbuvir; Tuberculosis